我们的团队
何欣，博士
Dr. Tu is a pioneer in the field of modern Chinese medicine research and invention. He’s a Director of Modern Research Center of Traditional Chinese Medicine, Peking University, Director of Department of Natural Medicinal Chemistry, School of Pharmacy, Peking University, Deputy Dean of Innovative Drug Research Institute, Peking University, Director (concurrently) of Modern Research Center of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Special Committee of Chinese Medicinal Materials, State Pharmacopoeia Commission Chairman, professor, doctoral supervisor, he’s regcnozied as “The father of Chinese Cistanche”, winner of the National Science Fund for Distinguished Young Scholars, winner of the second prize of the National Science and Technology Progress Award, the first Qihuang Scholar.
陈庚辉 博士
Dr. Chen is the CEO of The Derma Pharmaceuticals. He as a compound talent of scientific research and enterprise management, has the complete experience of successfully completing the overall research and development of the world’s first chemical drug (first-in-class) from discovery to industrialization, and the experience of successfully starting a business to stock listing and operating and managing listed companies . He has more than 40 invention patents involving multidisciplinary fields such as physiology, pharmacology, immunology, oncology and clinical medicine, and has more than 20 monographs and papers. Born in Hunan in 1963, he received his Ph.D. from Simon Fraser University in Canada in 1996. In 2008, Chen Genghui was named one of the Top 10 Outstanding Chinese Youths in Canada. He is the person in charge and completer of the major scientific and technological projects of the national “Twelfth Five-Year Plan” and “Major New Drug Creation”. In 2012, he was hired as a national special expert, Beijing special expert and China Federation of Returned Overseas Chinese special expert.
何欣，博士
何欣博士是汇鼎投资创始人及管理合伙人。 在创立汇鼎投资之前在鼎晖投资任高级合伙人，主导在医药、器械和医疗服务行业的投资，投资和管理近20个项目 加入鼎晖之前，是汇丰银行私募股权医药投资的全权合作伙伴；何欣博士还曾创立一家制药公司并任CEO，在美国和中国两地运营。
她主导投资的公司包括中和生物（上市）、信通（全球创新科技）、纽西恩药业（上市）、新世纪医疗（上市）、康宁医院（上市）、迈博医药（上市）、爱莫尔（国创科技）等。创业大赛奖、全球创新科技奖）、Hexawell Biotech（改革开放40年重大科技成果奖）、PHAGEPHARM（国家创新创业大赛奖）、舒瑞（全球创新科技奖）、ELPISCIENCE（全球创新科技奖） 、CureVac（上市，全球创新技术）、Carmine（全球创新技术）等众多行业领先者。
史蒂夫·林，DO
Dr. Steve Lin graduated from Western University of Health Sciences, where he obtained his medical training. With board certification in Internal Medicine, he has demonstrated a dedication to providing high-quality healthcare. His current focus on weight loss medicine demonstrates his commitment to assisting patients in leading healthier lives. Dr. Lin is known outside of medicine for his keen interest in investing in medical startups, demonstrating a multifaceted approach to life’s pursuits.